FDA approval for Orkambi in children with cystic fibrosis ages 12 to <24 months.- Vertex
Vertex Pharmaceuticals Incorporated announced the FDA approved expanded use of Orkmbi (lumacaftor/ivacaftor) to include children with cystic fibrosis (CF) ages 12 to <24 months who are homozygous for the f508del mutation (f f genotype) in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
Vertex Pharmaceuticals Incorporated announced the FDA approved expanded use of Orkmbi (lumacaftor/ivacaftor) to include children with cystic fibrosis (CF) ages 12 to <24 months who are homozygous for the f508del mutation f f genotype in the cystic fibrosis transmembrane conductance regulator cftr gene. orkambi was previously approved by the fda for use in people with cf ages 2 years and older with two copies of the f508del mutation.>
“Treating children with cystic fibrosis as early in life as possible is critically important, because early treatment has the potential to slow the progression of this devastating disease,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “Today’s approval is another important step on our journey to reach people of all ages living with cystic fibrosis who may benefit from our medicines.”
Orkambi was first approved in 2015 in the U.S. and is now available in more than 30 countries.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.